The CPRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CPRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CPRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CPRX Detailed Price Forecast - CNN Money||View CPRX Detailed Summary - Google Finance|
|View CPRX Detailed Summary - Yahoo! Finance||View CPRX Stock Research & Analysis - Zacks.com|
|View CPRX Trends & Analysis - Trade-Ideas||View CPRX Major Holders - Barrons|
|View CPRX Call Transcripts - NASDAQ||View CPRX Breaking News & Analysis - Seeking Alpha|
|View CPRX Annual Report - CompanySpotlight.com||View CPRX OTC Short Report - OTCShortReport.com|
|View CPRX Fundamentals - TradeKing||View CPRX SEC Filings - Bar Chart|
|View Historical Prices for CPRX - The WSJ||View Performance/Total Return for CPRX - Morningstar|
|View the Analyst Estimates for CPRX - MarketWatch||View the Earnings History for CPRX - CNBC|
|View the CPRX Earnings - StockMarketWatch||View CPRX Buy or Sell Recommendations - MacroAxis|
|View the CPRX Bullish Patterns - American Bulls||View CPRX Short Pain Metrics - ShortPainBot.com|
|View CPRX Stock Mentions - StockTwits||View CPRX Stock Mentions - PennyStockTweets|
|View CPRX Stock Mentions - Twitter||View CPRX Investment Forum News - Investor Hub|
|View CPRX Stock Mentions - Yahoo! Message Board||View CPRX Stock Mentions - Seeking Alpha|
|View Insider Transactions for CPRX - SECform4.com||View Insider Transactions for CPRX - Insider Cow|
|View CPRX Major Holdings Summary - CNBC||View Insider Disclosure for CPRX - OTC Markets|
|View Insider Transactions for CPRX - Yahoo! Finance||View Institutional Holdings for CPRX - NASDAQ|
|View CPRX Stock Insight & Charts - FinViz.com||View CPRX Investment Charts - StockCharts.com|
|View CPRX Stock Overview & Charts - BarChart||View CPRX User Generated Charts - Trading View|
Catalyst (CPRX) Up 16% Since Last Earnings Report: Can It Continue?
Posted on Thursday September 06, 2018
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks
Posted on Thursday August 30, 2018
Hedge fund manager Mitchell J. Blutt of the $1.5 billion Consonance Capital fund has made some intriguing portfolio shifts in the last quarter, including boosting his position in biopharma firm Catalyst Pharmaceuticals (NASDAQ:CPRX) and initiating stakes in drug makers Verastem (NASDAQ:VSTM) and Sesen Bio (NYSE:SESN). Blutt is seizing the opportunity with Catalyst, dialing up his hedge fund firm’s stake in the company to the tune of a 22% boost up.
Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference
Posted on Wednesday August 29, 2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw’s 20th Annual Global Investment Conference, which is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and spinal muscular atrophy (SMA) type 3.
Why Catalyst Pharmaceuticals (CPRX) Is a $6 Stock
Posted on Wednesday August 22, 2018
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have been waiting for two-and-a-half years since its marketing application was originally submitted to see the company's flagship candidate Firdapse approved, but they may not have to wait much longer -- the FDA is expected to make a decision by November 28. Catalyst had previously submitted an NDA for Firdapse off one positive pivotal trial in Lambert-Eaton myasthenic syndrome (LEMS). While the company believed this single trial, together with other information, would be adequate for approval, the FDA issued a Refuse-to-File letter in early 2016.